- Home
- MATX vs LEGN Comparison
MATX vs LEGN Comparison
Compare MATX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MATX | LEGN |
|---|---|---|
| Founded | 1882 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.9B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MATX | LEGN |
|---|---|---|
| Price | $177.83 | $23.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $150.00 | $61.33 |
| AVG Volume (30 Days) | 188.1K | ★ 2.3M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.81 | N/A |
| Revenue | ★ $3,344,500,000.00 | N/A |
| Revenue This Year | $4.65 | $42.68 |
| Revenue Next Year | $4.31 | $30.52 |
| P/E Ratio | $12.46 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $86.97 | $16.24 |
| 52 Week High | $180.21 | $45.30 |
Technical Indicators
Market Signals| Indicator | MATX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 64.88 | 66.20 |
| Support Level | $155.21 | $20.70 |
| Resistance Level | $178.22 | $26.72 |
| Average True Range (ATR) | 4.63 | 1.37 |
| MACD | -0.02 | 0.50 |
| Stochastic Oscillator | 77.16 | 68.61 |
Price Performance
Historical ComparisonAbout MATX Matson Inc.
Matson Inc is engaged in providing ocean transportation and logistics services. The company has two reportable business segments: Ocean Transportation and Logistics. The Ocean Transportation segment provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific. The Logistics segment offers long-haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.